Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Keros Therapeutics Inc (KROS)

Keros Therapeutics Inc (KROS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 650,754
  • Shares Outstanding, K 30,466
  • Annual Sales, $ 3,550 K
  • Annual Income, $ -187,350 K
  • EBIT $ 44 M
  • EBITDA $ 45 M
  • 60-Month Beta 0.89
  • Price/Sales 183.48
  • Price/Cash Flow N/A
  • Price/Book 0.93

Options Overview Details

View History
  • Implied Volatility 95.99% (-0.59%)
  • Historical Volatility 52.29%
  • IV Percentile 92%
  • IV Rank 46.34%
  • IV High 156.55% on 12/02/25
  • IV Low 43.69% on 06/13/25
  • Expected Move (DTE 21) 3.61 (16.91%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 164
  • Put/Call OI Ratio 0.58
  • Today's Open Interest 9,466
  • Open Int (30-Day) 17,484
  • Expected Range 17.75 to 24.97

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.49
  • Number of Estimates 7
  • High Estimate -0.16
  • Low Estimate -0.64
  • Prior Year -1.14
  • Growth Rate Est. (year over year) +57.02%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.75 +27.52%
on 12/02/25
22.55 -5.28%
on 12/08/25
+4.35 (+25.57%)
since 11/24/25
3-Month
13.60 +57.06%
on 10/17/25
22.55 -5.28%
on 12/08/25
+5.61 (+35.62%)
since 09/24/25
52-Week
9.12 +134.21%
on 04/09/25
22.55 -5.28%
on 12/08/25
+4.65 (+27.83%)
since 12/24/24

Most Recent Stories

More News
Keros Therapeutics Announces Final Results of Tender Offer

LEXINGTON, Mass., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), today announced the final results of its cash tender offer (the “Tender...

KROS : 21.36 (-0.09%)
Keros Therapeutics Announces Preliminary Results of Tender Offer

LEXINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), today announced the preliminary results of its cash tender offer (the “Tender...

KROS : 21.36 (-0.09%)
Keros Therapeutics Reports Third Quarter 2025 Financial Results

LEXINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing...

KROS : 21.36 (-0.09%)
Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million Shares

LEXINGTON, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing...

KROS : 21.36 (-0.09%)
Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital

Agrees to Repurchase of All Shares Held By ADAR1 Capital Management and Pontifax Venture Capital Plans to Commence Tender Offer to Repurchase up to $194 Million of Additional Shares LEXINGTON,...

KROS : 21.36 (-0.09%)
Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting

LEXINGTON, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel...

KROS : 21.36 (-0.09%)
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

LEXINGTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing...

KROS : 21.36 (-0.09%)
ADAR1 Sends Open Letter to Keros Board of Directors Urging the Board to Engage Constructively on Strategy, Capital Allocation and Board Refreshment

AUSTIN, Texas , Aug. 21, 2025 /PRNewswire/ -- ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1" or "we"), the largest stockholder of Keros Therapeutics (Nasdaq: KROS)...

KROS : 21.36 (-0.09%)
Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy

LEXINGTON, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics...

KROS : 21.36 (-0.09%)
Keros to Exclusively Prioritize the Clinical Advancement of KER-065

Company Discontinuing Development of Cibotercept (KER-012) Announces Board and Leadership Changes Designed to Support Streamlined Operational Structure and Strategic Realignment LEXINGTON,...

KROS : 21.36 (-0.09%)

Business Summary

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel treatments for hematological and musculoskeletal disorders. The company's product pipeline consists of KER-050, KER-047and KER-012 which are in clinical stage....

See More

Key Turning Points

3rd Resistance Point 21.89
2nd Resistance Point 21.69
1st Resistance Point 21.52
Last Price 21.36
1st Support Level 21.15
2nd Support Level 20.95
3rd Support Level 20.78

See More

52-Week High 22.55
Last Price 21.36
Fibonacci 61.8% 17.42
Fibonacci 50% 15.83
Fibonacci 38.2% 14.25
52-Week Low 9.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar